US pharma giant Eli Lilly has launched its highly anticipated diabetes and obesity drug, Mounjaro (tirzepatide), in India. The drug, available in 2.5 mg and 5 mg single-dose vials, is priced at ₹3,500 and ₹4,375, respectively. Since it is taken once a week, the monthly cost ranges from ₹14,000 to ₹17,500, significantly lower than the $1,000–$1,200 (₹86,000–1 lakh) price in the US.
Mounjaro is a first-of-its-kind treatment that activates two key hormone receptors (GIP and GLP-1) involved in regulating blood sugar and appetite. It is designed for type 2 diabetes, obesity, and overweight management. Clinical trials show that patients taking the highest dose (15 mg) lost an average of 21.8 kg in 72 weeks, while those on a lower dose (5 mg) lost 15.4 kg.
Obesity and diabetes are growing health concerns in India, with about 101 million people living with diabetes and nearly 100 million people affected by obesity. Many diabetes patients struggle with poor blood sugar control, increasing the risk of complications like heart disease, high blood pressure, and sleep disorders.
The Indian anti-obesity drug market has grown rapidly, from ₹137 crore in 2020 to ₹535 crore in 2024. The success of Novo Nordisk’s Rybelsus (oral semaglutide), launched in 2022, has been a game-changer, capturing 65% of the market. However, the patent for semaglutide will expire in March 2025, paving the way for Indian pharma companies like Mankind Pharma, Alkem Labs, and Dr. Reddy’s to introduce cheaper alternatives.
Mounjaro works by improving insulin secretion, reducing hunger, and slowing digestion, leading to better blood sugar control and weight loss. Lilly aims to collaborate with the Indian government and healthcare industry to increase awareness and accessibility of such treatments.
With growing demand for effective weight-loss and diabetes treatments, Mounjaro is set to compete in a rapidly expanding market where medical solutions for obesity are gaining wider acceptance.
